• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成熟对儿科患者药物处置的影响。

Effect of maturation on drug disposition in pediatric patients.

作者信息

Stewart C F, Hampton E M

机构信息

Department of Clinical Pharmacy, College of Pharmacy, University of Tennessee, Memphis 38163.

出版信息

Clin Pharm. 1987 Jul;6(7):548-64.

PMID:3319364
Abstract

Maturational changes in the physiologic processes that govern drug disposition in pediatric patients are described, and evaluation of data from pediatric drug studies is discussed. Gastrointestinal absorption depends on gastric pH, gastric emptying time, intestinal transit time, and gastrointestinal enzymatic activity; the overall effect of age-related alterations in these variables is poorly understood. Maturational changes in the skin affect percutaneous absorption. Distribution of drugs is affected by alterations in vascular perfusion, body composition, tissue binding, and plasma protein binding. For most water-soluble drugs, volume of distribution is increased in neonates. Age-related changes in biotransformation are complex because the rate of development of phase 1 and phase 2 metabolic pathways varies and metabolic pathways may be induced by in utero exposure to inducing agents. For most drugs, biotransformation is decreased in the neonate, increases from one to five years of age, and decreases after puberty to adult values. The kidneys of neonates are inefficient at drug elimination, leading initially to prolonged elimination half-lives of many drugs. Clearance of some drugs may be greater in infants than in older children and adults because of disproportionate development of renal filtration and secretion in relation to reabsorption. Few data on maturational changes in physiologic processes that affect drug disposition are available for any one drug in a specific pediatric population. In the development of research protocols, careful attention should be paid to the design limitations of published studies.

摘要

描述了小儿患者体内药物处置相关生理过程的成熟变化,并讨论了儿科药物研究数据的评估。胃肠道吸收取决于胃内pH值、胃排空时间、肠道转运时间和胃肠道酶活性;这些变量随年龄变化的总体影响尚不清楚。皮肤的成熟变化会影响经皮吸收。药物分布受血管灌注、身体组成、组织结合和血浆蛋白结合变化的影响。对于大多数水溶性药物,新生儿的分布容积会增加。生物转化的年龄相关变化很复杂,因为I相和II相代谢途径的发育速度不同,且代谢途径可能因子宫内接触诱导剂而被诱导。对于大多数药物,新生儿的生物转化能力降低,1至5岁时增加,青春期后降至成人水平。新生儿的肾脏在药物消除方面效率低下,最初导致许多药物的消除半衰期延长。由于肾滤过和分泌相对于重吸收的发育不成比例,一些药物在婴儿体内的清除率可能高于大龄儿童和成人。对于特定儿科人群中的任何一种药物,关于影响药物处置的生理过程成熟变化的数据都很少。在制定研究方案时,应仔细关注已发表研究的设计局限性。

相似文献

1
Effect of maturation on drug disposition in pediatric patients.成熟对儿科患者药物处置的影响。
Clin Pharm. 1987 Jul;6(7):548-64.
2
Drug disposition during the perinatal period.围产期的药物处置
Int J Biol Res Pregnancy. 1981;2(1):1-14.
3
Linezolid pharmacokinetics in pediatric patients: an overview.利奈唑胺在儿科患者中的药代动力学:综述。
Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S153-7. doi: 10.1097/01.inf.0000086954.43010.63.
4
Prescribing for children: issues in pediatric pharmacology.儿童用药:儿科药理学中的问题
Nurse Pract. 1997 Mar;22(3):16-8, 23, 26-8 passim.
5
Clonidine disposition in children; a population analysis.可乐定在儿童体内的处置;一项群体分析。
Paediatr Anaesth. 2007 Oct;17(10):924-33. doi: 10.1111/j.1460-9592.2007.02251.x.
6
Consideration of sheep as a minor species: comparison of drug metabolism and disposition with other domestic ruminants.将绵羊视为次要物种的考量:药物代谢及处置与其他家养反刍动物的比较。
Vet Hum Toxicol. 1993;35 Suppl 2:40-56.
7
The effects of extremes of age on drug action.年龄极端情况对药物作用的影响。
Methods Find Exp Clin Pharmacol. 1980 Dec;2(6):303-12.
8
Optimizing pediatric dosing: a developmental pharmacologic approach.优化儿科用药剂量:一种发育药理学方法。
Pharmacotherapy. 2009 Jun;29(6):680-90. doi: 10.1592/phco.29.6.680.
9
Influence of obesity on drug disposition.肥胖对药物处置的影响。
Clin Pharm. 1987 Sep;6(9):706-14.
10
Determinants of variability in clearance of exogenous compounds in neonates.新生儿中外源性化合物清除率变异性的决定因素。
Verh K Acad Geneeskd Belg. 2009;71(3):141-64.

引用本文的文献

1
Comparison of the CYP3A Selective Inhibitors CYP3cide, Clobetasol, and Azamulin for Their Potential to Distinguish CYP3A7 Activity in the Presence of CYP3A4/5.比较 CYP3A 选择性抑制剂 CYP3cide、氯倍他索和阿扎米林在 CYP3A4/5 存在下区分 CYP3A7 活性的潜力。
Drug Metab Dispos. 2024 Oct 16;52(11):1224-1233. doi: 10.1124/dmd.124.001598.
2
Population pharmacokinetics of FCN-159, a MEK1/2 inhibitor, in adult patients with advanced melanoma and neurofibromatosis type 1 (NF1) and model informed dosing recommendations for NF1 pediatrics.MEK1/2抑制剂FCN-159在晚期黑色素瘤和1型神经纤维瘤病(NF1)成年患者中的群体药代动力学以及NF1儿科患者的模型指导给药建议。
Front Pharmacol. 2023 Jan 23;14:1101991. doi: 10.3389/fphar.2023.1101991. eCollection 2023.
3
Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations.基于生理的羟氯喹啉治疗疟疾的药代动力学建模及不同人群的优化给药方案
J Pers Med. 2022 May 14;12(5):796. doi: 10.3390/jpm12050796.
4
Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening.鉴定荧光探针底物以开发高效高通量的新生儿肝 CYP3A7 抑制筛选检测方法。
Sci Rep. 2021 Sep 30;11(1):19443. doi: 10.1038/s41598-021-98219-x.
5
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.索拉非尼在儿童和青少年难治/复发性白血病或实体瘤恶性肿瘤患者中的群体药代动力学和皮肤毒性。
Clin Cancer Res. 2019 Dec 15;25(24):7320-7330. doi: 10.1158/1078-0432.CCR-19-0470. Epub 2019 Aug 27.
6
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group.急性淋巴细胞白血病婴儿大剂量甲氨蝶呤的群体药代动力学强调了床边个体化剂量调整的必要性:来自儿童肿瘤学组的报告。
Clin Pharmacokinet. 2019 Jul;58(7):899-910. doi: 10.1007/s40262-018-00734-0.
7
Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.CYP2C19、UGT1A8和UGT2B7对癫痫患儿丙戊酸清除率的影响:一项群体药代动力学模型研究
Eur J Clin Pharmacol. 2018 Aug;74(8):1029-1036. doi: 10.1007/s00228-018-2440-6. Epub 2018 Apr 17.
8
Relevance of CYP2C9 Function in Valproate Therapy.CYP2C9 功能与丙戊酸治疗的相关性。
Curr Neuropharmacol. 2019;17(1):99-106. doi: 10.2174/1570159X15666171109143654.
9
Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus.2型糖尿病儿童及青少年抗高血糖药物的临床药代动力学与药效学
Clin Pharmacokinet. 2017 Jun;56(6):561-571. doi: 10.1007/s40262-016-0472-6.
10
Advances in Drug Discovery and Development for Pediatric Tuberculosis.儿童结核病药物研发进展
Mini Rev Med Chem. 2016;16(6):481-97. doi: 10.2174/1389557515666150722101723.